{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:36:43Z","timestamp":1775065003219,"version":"3.50.1"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"S2","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radioimmunotherapy (RIT) combines the use of targeted monoclonal antibodies with radionuclides for the treatment of non-Hodgkin\u2019s lymphoma (NHL), taking advantage of its inherent radiosensitivity. A number of trials have shown significantly higher response rates and longer progression-free survival times in patients treated with the CD20-targeted radioimmunoconjugate yttrium-90-ibritumomab tiuxetan compared with the standard of care. Furthermore, these benefits have also been shown in heavily pretreated patients who relapsed or were resistant to rituximab. Currently, a number of different treatment regimens and strategies are available for the treatment of NHL patients. Therefore, in an attempt to minimize toxicity, maximize efficacy, and improve survival, it is crucial to appropriately select patients who are good candidates for individual treatment approaches. A strategy for patient selection has been developed, including the use of existing patient assessment tools, such as the Follicular Lymphoma International Prognostic Index, to determine the optimal regimen for patients with follicular lymphoma according to their disease characteristics and physical condition. Patients who are fit make ideal candidates for potentially curative regimens, which include induction chemotherapy with or without immunotherapy followed by RIT consolidation and, potentially, maintenance therapy. Patients who are considered \u201ccompromised\u201d would also benefit from induction treatment and RIT consolidation, with a view to reducing the lymphoma burden and decreasing the risk for disease progression. \u201cFrail\u201d patients would be better suited to supportive therapy to control symptoms. This paper explores factors that should be considered when assessing whether a patient is a good candidate for treatment with RIT, and aids physicians in the selection of the most appropriate therapy for each patient group.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-s2-4","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T21:40:21Z","timestamp":1255124421000},"page":"4-16","source":"Crossref","is-referenced-by-count":15,"title":["Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1093","volume":"14","author":[{"given":"Stephanie A.","family":"Gregory","sequence":"first","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Hohloch","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"2021122207231657400_R1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","article-title":"Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas","volume":"69","author":"Press","year":"1987","journal-title":"Blood"},{"key":"2021122207231657400_R2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"EMBO J"},{"key":"2021122207231657400_R3","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"2021122207231657400_R4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/biot.200700043","article-title":"Yttrium 90 ibritumomab tiuxetan (Zevalin\u00ae): A new bullet in the fight against malignant lymphoma?","volume":"2","author":"Chapuy","year":"2007","journal-title":"Biotechnol J"},{"key":"2021122207231657400_R5","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): Survival analyses with extended follow-up (F\/Up) of 7 years [abstract 486]","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"2021122207231657400_R6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: A phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"2021122207231657400_R8","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122207231657400_R10","volume-title":"Rituximab Prescribing Information","author":"U.S. Food and Drug Administration"},{"key":"2021122207231657400_R11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1387-2656(04)10011-2","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma: Clinical development of the Zevalin regimen","volume":"10","author":"Theuer","year":"2004","journal-title":"Biotechnol Annu Rev"},{"key":"2021122207231657400_R12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001622-199909000-00009","article-title":"Radioimmunotherapy for lymphoma","volume":"11","author":"Zelenetz","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"2021122207231657400_R13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1148\/108.3.675","article-title":"Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas","volume":"108","author":"Fuks","year":"1973","journal-title":"Radiology"},{"key":"2021122207231657400_R14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hon.2900120104","article-title":"Prognosis in low grade non-Hodgkin\u2019s lymphoma: Relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level","volume":"12","author":"Parker","year":"1994","journal-title":"Hematol Oncol"},{"key":"2021122207231657400_R15","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood.V87.9.3640.bloodjournal8793640","article-title":"Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies","volume":"87","author":"White","year":"1996","journal-title":"Blood"},{"key":"2021122207231657400_R16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122207231657400_R17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","article-title":"Treatment of refractory non-Hodgkin\u2019s lymphoma with radiolabeled MB-1 (anti-CD37) antibody","volume":"7","author":"Press","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"issue":"10 suppl","key":"2021122207231657400_R19","first-page":"3292s","article-title":"Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-\/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin\u2019s lymphoma","volume":"5","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122207231657400_R20","first-page":"1801","article-title":"Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides","volume":"34","author":"Rao","year":"1993","journal-title":"J Nucl Med"},{"key":"2021122207231657400_R21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0883-2897(91)90107-V","article-title":"The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates","volume":"18","author":"Harrison","year":"1991","journal-title":"Int J Rad Appl Instrum B"},{"key":"2021122207231657400_R22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0883-2897(91)90065-S","article-title":"Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies","volume":"18","author":"Roselli","year":"1991","journal-title":"Int J Rad Appl Instrum B"},{"key":"2021122207231657400_R23","first-page":"268","article-title":"Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution","volume":"40","author":"Carrasquillo","year":"1999","journal-title":"J Nucl Med"},{"key":"2021122207231657400_R24","first-page":"1017","article-title":"Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin\u2019s lymphoma","volume":"15","author":"Chinn","year":"1999","journal-title":"Int J Oncol"},{"key":"2021122207231657400_R25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"2021122207231657400_R26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122207231657400_R27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-0038-1625737","article-title":"[Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial]","volume":"45","author":"Geworski","year":"2006","journal-title":"Nuklearmedizin"},{"issue":"suppl 4","key":"2021122207231657400_R28","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1080\/10428140310001616935","article-title":"The role of nuclear medicine in the treatment of non-Hodgkin\u2019s lymphoma (NHL)","volume":"44","author":"Bischof Delaloye","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2021122207231657400_R29","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin\u2019s lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R30","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R31","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"2021122207231657400_R32","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"2021122207231657400_R33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"2021122207231657400_R35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R36","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122207231657400_R38","first-page":"449s","article-title":"I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years [abstract 8033]","volume":"25","author":"Kaminski","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122207231657400_R39","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1200\/JCO.2005.01.0892","article-title":"Re-treatment with I-131 tositumomab in patients with non-Hodgkin\u2019s lymphoma who had previously responded to I-131 tositumomab","volume":"23","author":"Kaminski","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021122207231657400_R40","first-page":"CD003805","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122207231657400_R41","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R42","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood.V112.11.2002.2002","article-title":"Extended follow-up of the international randomized phase 3 First-line Indolent Trial (FIT) shows durable benefit of 90Y-ibritumomab tiuxetan (Zevalin\u00ae) consolidation of first remission in advanced stage follicular non-Hodgkin\u2019s lymphoma [abstract 2002]","volume":"112","author":"Morschhauser","year":"2008","journal-title":"Blood"},{"key":"2021122207231657400_R43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R44","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R45","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"2021122207231657400_R46","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14 suppl","key":"2021122207231657400_R47","article-title":"Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin\u2019s lymphoma (NHL) [abstract 6520]","volume":"22","author":"Link","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122207231657400_R48","first-page":"17","article-title":"Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin\u2019s lymphoma: A review of the evidence","volume":"14","author":"Morschhauser","journal-title":"The Oncologist"},{"key":"2021122207231657400_R49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122207231657400_R50","volume-title":"Primary Rituximab and Maintenance (PRIMA)"},{"key":"2021122207231657400_R51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1360.1360","article-title":"A prospective study evaluating the safety and efficacy of combination therapy with fludarabine plus mitoxantrone followed by yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) and maintenance rituximab as front line therapy for patients with intermediate or high risk follicular non-Hodgkin\u2019s lymphoma [abstract 1360]","volume":"110","author":"Gregory","year":"2007","journal-title":"Blood"},{"key":"2021122207231657400_R52","volume-title":"The RIT network provides real life clinical data on radioimmunotherapy for lymphoma: An international registry for radioimmunotherapy-treated patients","author":"Hohloch","year":"2008"},{"key":"2021122207231657400_R53","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122207231657400_R54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V92.2.405","article-title":"A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"2021122207231657400_R55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.2000.18.2.325","article-title":"Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: Role of the tumor necrosis factor ligand-receptor system","volume":"18","author":"Voog","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R56","first-page":"538","article-title":"MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine","volume":"37","author":"Stabin","year":"1996","journal-title":"J Nucl Med"},{"key":"2021122207231657400_R57","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"2021122207231657400_R58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1040-8428(01)00107-X","article-title":"Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin\u2122 radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"39","author":"Wiseman","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4 Suppl","key":"2021122207231657400_R59","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","article-title":"Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma","volume":"94","author":"Wiseman","year":"2002","journal-title":"Cancer"},{"key":"2021122207231657400_R60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/108497803765036337","article-title":"Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin\u2122) radioimmunotherapy for patients with non-Hodgkin\u2019s lymphoma and mild thrombocytopenia","volume":"18","author":"Wiseman","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122207231657400_R61","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma: Combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"issue":"suppl 17","key":"2021122207231657400_R62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2003.10.004","article-title":"Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin)","volume":"30","author":"Gregory","year":"2003","journal-title":"Semin Oncol"},{"issue":"19 suppl","key":"2021122207231657400_R63","doi-asserted-by":"crossref","first-page":"7146s","DOI":"10.1158\/1078-0432.CCR-1004-0003","article-title":"Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy","volume":"11","author":"Jacobs","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122207231657400_R64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1705919","article-title":"Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin\u2019s lymphoma","volume":"41","author":"Shimoni","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2021122207231657400_R65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/10428190601158639","article-title":"Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin\u2019s lymphoma following high-dose chemotherapy and autologous stem cell transplantation","volume":"48","author":"Vose","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2021122207231657400_R66","volume-title":"Bexxar\u00ae [label]","author":"Food and Drug Administration"},{"key":"2021122207231657400_R67","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/cbr.2007.359","article-title":"Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin\u2019s lymphoma","volume":"22","author":"Emmanouilides","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122207231657400_R68","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R69","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2021122207231657400_R70","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"16 suppl","key":"2021122207231657400_R71","article-title":"Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial [abstract 6577]","volume":"23","author":"Shipley","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207231657400_R72","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3061.3061","article-title":"90Y ibritumomab tiuxetan as initial treatment for follicular lymphoma (ZEUS Protocol). An Italian Cooperative Study Group [abstract 3061]","volume":"112","author":"Carella","year":"2008","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122207231657400_R73","doi-asserted-by":"crossref","first-page":"ii63","DOI":"10.1093\/annonc\/mdm041","article-title":"Newly diagnosed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"18","author":"Hiddemann","year":"2007","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"2021122207231657400_R74","doi-asserted-by":"crossref","first-page":"ii77","DOI":"10.1093\/annonc\/mdn096","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122207231657400_R75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","article-title":"Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma\u2014role of radioimmunotherapy","volume":"86","author":"Dreyling","year":"2007","journal-title":"Ann Hematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-S2-4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-S2-4","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S2\/4\/41841479\/oncolo_14_s2_4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/S2\/4\/41841479\/oncolo_14_s2_4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T03:23:27Z","timestamp":1685157807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/S2\/4\/6398784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":75,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2009,10,1]]},"published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-s2-4","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,10,1]]},"published":{"date-parts":[[2009,10,1]]}}}